U.S. markets closed

  • S&P 500

    3,951.57
    +34.93 (+0.89%)
     

  • Dow 30

    32,244.58
    +382.60 (+1.20%)
     

  • Nasdaq

    11,675.54
    +45.02 (+0.39%)
     

  • Russell 2000

    1,744.99
    +19.10 (+1.11%)
     

  • Crude Oil

    67.55
    +0.81 (+1.21%)
     

  • Gold

    1,983.20
    +9.70 (+0.49%)
     

  • Silver

    22.64
    +0.17 (+0.77%)
     

  • EUR/USD

    1.0726
    +0.0055 (+0.51%)
     

  • 10-Yr Bond

    3.4810
    +0.0860 (+2.53%)
     

  • GBP/USD

    1.2276
    +0.0101 (+0.83%)
     

  • USD/JPY

    131.4450
    -0.3580 (-0.27%)
     

  • Bitcoin USD

    27,846.43
    -566.39 (-1.99%)
     

  • CMC Crypto 200

    604.69
    +5.02 (+0.84%)
     

  • FTSE 100

    7,403.85
    +68.45 (+0.93%)
     

  • Nikkei 225

    26,945.67
    -388.12 (-1.42%)
     

Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Baudax Bio, Inc.
·1 min read

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

The presentation will be made available for on-demand listening beginning Monday, September 13, 2021 at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

CONTACTS:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com


Recommended Stories